A Labile Endogenous Na-pump Inhibitor in Man

  • S. W. Graves
  • P. A. Soszynski
  • Q. F. Tao
  • G. H. Williams
  • N. K. Hollenberg

Abstract

A circulating, endogenous sodium pump inhibitor (ESPI) has been implicated in the pathogenesis of essential hypertension (3). Efforts to identify this factor have generated a bewildering array of chemically different candidates (1). Previous efforts to isolate such a factor for further characterization have used techniques, which while appropriate for the purification of stable chemical species, have been too long and/or ineffective in protecting chemically labile species. We have developed a procedure to purify ESPI from human fluids that would be rapid and provide protection for air and thermally sensitive chemical species to ascertain whether such compounds exist and to allow for their study. We had previously carried out a clinical study in which we isolated an ESPI from human peritoneal dialysate (PD) from patients with sustained extracellular fluid volume expansion (6). PD levels of this ESPI were correlated with volume status, blood pressure, and serum Na+/K+-ATPase inhibitory activity. Additionally, it appeared to be chemically unstable. We have continued to use this same paradigm to insure isolation of a volume-sensitive ESPI and to exploit PD as a source because it is rapidly available and readily processed.

Keywords

Hydrolysis HPLC Enzymatic Degradation Kelly Preeclampsia 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Goto A, Yamada K, Yagi N, Yoshioka M, Sugimoto T. Physiology and pharmacology of endogenous digitalis-like factors. Pharmacol Rev 1992; 44: 377–399.Google Scholar
  2. 2.
    Graves SW, Williams GH. An endogenous ouabain-like factor associated with hypertensive pregnancies. J Clin Endo Metab 1984; 59: 1070–1074.CrossRefGoogle Scholar
  3. 3.
    Graves SW, Williams GH. Endogenous digitalis-like natriuretic factors. Ann Rev Med 1987; 38: 433–444.PubMedCrossRefGoogle Scholar
  4. 4.
    Graves SW, Eder JP, Schryber SM, Sharma K, Brena A, Antman KH, Peters WP. Endogenous digoxin-like immunoreactive factor and digitalis-like factor associated with the hypertension of patients receiving multiple alkylating agents as part of autologous bone marrow transplantation. Clin Sci 1989;77: 501–507.Google Scholar
  5. 5.
    Graves SW, Seely EW, Williams GH, Hollenberg NK. A purified, high affinity inhibitor of Na+/K+-ATPase causes vasoconstriction. Clin Exp Hypertens 1991; B10: 173 (Abstract).Google Scholar
  6. 6.
    Graves SW, Glatter KA, Lazarus JM, Williams GH, Hollenberg NK. Volume expansion in renal failure patients: a paradigm for a clinically relevant Na+/K+-ATPase inhibitor. J Cardiovas Pharmacol 1993; 22(S2): S54–S57.CrossRefGoogle Scholar
  7. 7.
    Kelly RA, Smith TW. Is ouabain the endogenous digitalis? Circulation 1992; 86: 794–797.Google Scholar

Copyright information

© Dietrich Steinkopff Verlag GmbH & Co. KG, Darmstadt 1994

Authors and Affiliations

  • S. W. Graves
    • 2
  • P. A. Soszynski
    • 2
  • Q. F. Tao
    • 2
  • G. H. Williams
    • 2
  • N. K. Hollenberg
    • 1
  1. 1.Medicine (Endocrine-Hypertension Division)Harvard Medical School, Brigham and Women’s HospitalBostonUSA
  2. 2.Departments of RadiologyHarvard Medical School, Brigham and Women’s HospitalBostonUSA

Personalised recommendations